<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702451</url>
  </required_header>
  <id_info>
    <org_study_id>CLIPL-01-002</org_study_id>
    <nct_id>NCT04702451</nct_id>
  </id_info>
  <brief_title>Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation</brief_title>
  <acronym>Tailored-AF</acronym>
  <official_title>Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Volta Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CardiaBase</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Volta Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of&#xD;
      the left atrium without attempting to identify patient-specific areas of interest. This&#xD;
      procedure is referred to as Pulmonary Vein Isolation (PVI).&#xD;
&#xD;
      The hypothesis in this Study is that a tailored ablation strategy targeting areas of&#xD;
      spatio-temporal dispersion in combination with PVI is superior to an anatomical ablation&#xD;
      strategy targeting PVI alone for the treatment of persistent AF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from documented AF after one ablation procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from documented AF episodes &gt; 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF/AT after one ablation procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from documented AF/AT episodes &gt; 30 seconds, with or without AADs, 12 months after a single index ablation procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF/AT after one or more ablation procedure(s)</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from documented AF/AT episodes &gt; 30 seconds, after one procedure or more, with or without AADs, at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF after one or more ablation procedure(s)</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from documented AF episodes &gt; 30 seconds, after one procedure or more, with or without AADs, at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications (safety composite endpoint)</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of complications at 12 months: death, cerebrovascular events, or serious treatment-related adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Tailored</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tailored ablation strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anatomical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anatomical ablation strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dispersion ablation + PVI</intervention_name>
    <description>Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation</description>
    <arm_group_label>Tailored</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VX1</intervention_name>
    <description>VX1-based dispersion mapping</description>
    <arm_group_label>Tailored</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI</intervention_name>
    <description>Pulmonary vein antrum isolation</description>
    <arm_group_label>Anatomical</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years of age or older candidates for a first AF ablation&#xD;
&#xD;
          -  Symptomatic AF, refractory to at least one antiarrhythmic medication&#xD;
&#xD;
          -  Persistent or long-standing persistent AF with documentation of (ECG, Holter,&#xD;
             physician's letter): AF duration of ≥ 3 months and ≤ 5 years or 1 effective&#xD;
             cardioversion followed by AF recurrence lasting ≥ 3 months&#xD;
&#xD;
          -  Continuous anticoagulation with warfarin (INR 2-3) or NOAC for &gt; 4 weeks prior to&#xD;
             ablation&#xD;
&#xD;
          -  Patients must be able and willing to provide written informed consent to participate&#xD;
             in the clinical trial&#xD;
&#xD;
          -  Maximum of 70% of patients (240 patients) in persistent AF &lt; 12 months (&gt;30% of&#xD;
             long-standing persistent AF ≥ 12 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal and short-standing AF &lt; 3 months&#xD;
&#xD;
          -  Long-standing persistent AF &gt; 5 years&#xD;
&#xD;
          -  ≥ 2 previous ineffective cardioversion sessions in case of undetermined AF duration&#xD;
&#xD;
          -  Severe obesity (BMI &gt; 40)&#xD;
&#xD;
          -  Very dilated Left Atrium (LA)(e.g. LA diameter &gt; 60 mm and/or LA surface &gt; 40 cm2&#xD;
             determined by 2D echocardiography)&#xD;
&#xD;
          -  Patients with AF secondary to an obvious reversible cause&#xD;
&#xD;
          -  Inadequate anticoagulation as defined in the inclusion criteria&#xD;
&#xD;
          -  LA thrombus on Transesophageal Echocardiography (TEE) or CT Scan prior to procedure&#xD;
&#xD;
          -  Contraindications to anticoagulation (heparin, warfarin or NOAC)&#xD;
&#xD;
          -  Patients who are or may potentially be pregnant&#xD;
&#xD;
          -  Previous surgical or catheter ablation for AF&#xD;
&#xD;
          -  Any cardiac surgery within the past 2 months (60 days) (includes PCI)&#xD;
&#xD;
          -  Myocardial infarction within the past 2 months (60 days)&#xD;
&#xD;
          -  Previous AV valve surgery&#xD;
&#xD;
          -  History of blood clotting or bleeding abnormalities&#xD;
&#xD;
          -  Documented thromboembolic event (including TIA) within the past 12 months (365 days)&#xD;
&#xD;
          -  Rheumatic Heart Disease&#xD;
&#xD;
          -  Chronic severe Heart Failure (NYHA functional class IV and/or LVEF &lt; 25%)&#xD;
&#xD;
          -  Awaiting cardiac transplantation or other cardiac surgery within the next 12 months&#xD;
             (365 days)&#xD;
&#xD;
          -  Unstable angina within the past month&#xD;
&#xD;
          -  Acute illness or active systemic infection or sepsis&#xD;
&#xD;
          -  AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          -  Diagnosed atrial myxoma&#xD;
&#xD;
          -  Significant severe pulmonary disease, (e.g. patients with restrictive pulmonary&#xD;
             disease, constrictive or chronic obstructive pulmonary disease in GOLD stage IV) or&#xD;
             any other disease or malfunction of the lungs or respiratory system that produces&#xD;
             chronic symptoms (e.g. unstable or untreated sleep apnea)&#xD;
&#xD;
          -  Significant congenital anomaly or medical problem that in the opinion of the&#xD;
             investigator would preclude enrollment&#xD;
&#xD;
          -  Enrollment in an investigational study evaluating another device, biologic, or drug&#xD;
&#xD;
          -  Presence of intramural thrombus, tumor or other abnormality or condition that&#xD;
             precludes vascular access, or manipulation of the catheter&#xD;
&#xD;
          -  Life expectancy or other disease processes likely to limit survival to less than 12&#xD;
             months&#xD;
&#xD;
          -  Acute Covid-19 infection (fever and/or biological inflammatory syndrome, and positive&#xD;
             test documented)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Deisenhofer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Deisenhofer, MD</last_name>
    <phone>+49 89 1218</phone>
    <phone_ext>2020</phone_ext>
    <email>deisenhofer@dhm.mhn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lennox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Queens Hospital</name>
      <address>
        <city>Queens</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pôle Santé République</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Philibert</name>
      <address>
        <city>Lomme</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel - Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé du Confluent</name>
      <address>
        <city>Nantes</city>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint George</name>
      <address>
        <city>Nice</city>
        <zip>06105</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Rhéna</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Isala Hartcentrum Zwolle</name>
      <address>
        <city>Zwolle</city>
        <zip>8025</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Seitz J, Bars C, Théodore G, Beurtheret S, Lellouche N, Bremondy M, Ferracci A, Faure J, Penaranda G, Yamazaki M, Avula UM, Curel L, Siame S, Berenfeld O, Pisapia A, Kalifa J. AF Ablation Guided by Spatiotemporal Electrogram Dispersion Without Pulmonary Vein Isolation: A Wholly Patient-Tailored Approach. J Am Coll Cardiol. 2017 Jan 24;69(3):303-321. doi: 10.1016/j.jacc.2016.10.065.</citation>
    <PMID>28104073</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <keyword>Catheter Ablation</keyword>
  <keyword>Electrogram dispersion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

